Capital Impact Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-24,540
| Closed | -$399K | – | 2 |
|
|
2024
Q2 | $399K | Buy |
24,540
+14,854
| +153% | +$241K | 1.12% | 48 |
|
|
2024
Q1 | $179K | Hold |
9,686
| – | – | 0.23% | 87 |
|
|
2023
Q4 | $303K | Hold |
9,686
| – | – | 0.4% | 86 |
|
|
2023
Q3 | $202K | Sell |
9,686
-9,686
| -50% | -$202K | 0.34% | 98 |
|
|
2023
Q2 | $464K | Hold |
19,372
| – | – | 0.51% | 98 |
|
|
2023
Q1 | $365K | Buy |
19,372
+1,160
| +6% | +$21.8K | 0.45% | 107 |
|
|
2022
Q4 | $290K | Sell |
18,212
-2,842
| -13% | -$45.2K | 0.28% | 152 |
|
|
2022
Q3 | $315K | Sell |
21,054
-11,543
| -35% | -$173K | 0.31% | 134 |
|
|
2022
Q2 | $459K | Buy |
32,597
+3,643
| +13% | +$51.3K | 0.42% | 108 |
|
|
2022
Q1 | $701K | Buy |
28,954
+6,879
| +31% | +$167K | 0.51% | 92 |
|
|
2021
Q4 | $515K | Buy |
+22,075
| New | +$515K | 0.36% | 83 |
|